

DIVA Investor Conference

December 1, 2023



Participants

Vice Chairman Gene Chen

Admin VP & Spokesman Michael Mai

Finance Senior Manager Angel Chiang

Agenda

—. Company Profile

Admin VP &

Michael Mai

二. 2023 Q1~Q3 Financial Results

Spokesman

三. Business Update and Outlook

四. Q&A

Vice Chairman Gene Chen



Safe Harbor Notice

We have made forward-looking statements in the presentation. Our forward- looking statements contain information regarding, among other things, our financial conditions, future expansion plans and business strategies. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that these expectations and projections are reasonable, such forward-looking statements are inherently subject to risks, uncertainties, and assumptions about us.

We undertake no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events might not occur and our actual results could differ materially from those anticipated in these forward-looking statements.





—.Company Profile

Admin VP & Spokesman Michael Mai



DIVA Labs.

Focused on providing high quality precision displays to meet the product requirements of global OEM and ODM customers

		_	
Year			95
	ESTA		

IPO Year 2013

(Ticker 4153)

Capital (NTD) 618M

No. of Employees 150+

Global Presence

Manufacturing Sites: Taiwan

Sales Offices: 3 Locations Worldwide

R&D: Taiwan

Revenue Breakdown by Geography:

	2021	2022	2023
Americas	49%	43%	39%
Europe	34%	39%	42%
Taiwan	8%	8%	6%
Others	9%	10%	13%

2023 First Three Quarters Revenue

NTD\$ 689M (USD\$ 22.4M)

2022 Revenue

NTD\$ 949M (USD\$31.9M)





二. 2023 Q1-Q3 Financial Results

Admin VP & Spokesman Michael Mai



2023 Q1-Q3 Highlights



Revenue, operating income and net income attributable to the parent company for the first three quarters of the year

- Revenue grew 5%, operating income increased 102%, and net income attributable to the parent company increased 88%.
- Return on equity (ROE) 5.2%.



Revenue grew 5% YoY in the first three quarters

• **Revenue growth:** 5% for medical, 1% for industrial, and -1% for parts and components.



Consolidated Statement of Comprehensive Income(Quarterly)

Unit: NT\$Million

Net Sales
Cost of Goods Sold
Gross Margin
Operating Expenses
Operating Income
Net non-operating Income
Profit(Loss) before Tax
Net Income
Net income attributable to DIVA
EPS (NT\$) (a)

2023 Q3							
207	100%						
(146)							
62	30%						
(35)	-17%						
26	13%						
(1)							
25	12%						
19	9%						
19	9%						
\$0.33							

2022 Q3					
236	100%				
(168)					
69	29%				
(48)	-20%				
21	9%				
8					
28	12%				
23	10%				
23	10%				
\$0.39					

YoY					
amt	g%				
(29)	-12%				
22					
(7)	-10%				
13					
5	27%				
(9)					
(3)	-11%				
(3)	-14%				
(3)	-14%				
-\$0.06					

2023 Q2						
100%						
29%						
-24%						
5%						
3%						
5%						
5%						

QoQ						
amt	g%					
(26)	-11%					
20						
(6)	-9%					
20						
15	125%					
3						
17	214%					
8	65%					
8	65%					
\$0.13						

(a) EPS was calculated based on total weighted-averaged outstanding shares



Consolidated Statement of Comprehensive Income (YTD)

Unit: NT\$Million

Net Sales

Cost of Goods Sold

Gross Margin

Operating Expenses

Operating Income

Net non-operating Income

Profit(Loss) before Tax

Net Income

Net income attributable to DIVA

EPS (NT\$) (a)

2023 Q3							
689	100%						
(485)							
204	30%						
(137)	-20%						
67	10%						
(6)							
61	9%						
53	8%						
53	8%						
\$0.90							

2022 Q3					
654	100%				
(489)					
165	25%				
(131)	-20%				
33	5%				
3					
36	6%				
28	4%				
28	4%				
\$0.48					


YoY						
amt	g%					
35	5%					
4						
39	24%					
(5)						
34	102%					
(9)						
25	69%					
25	88%					
25	88%					
\$0.42						

(a) EPS was calculated based on total weighted-averaged outstanding shares




Revenue and Operating Income

Unit: NT\$ Million



Revenue

Unit: NT\$ Million



Operating Income




Consolidated Balance Sheet Highlights

Unit: NT\$ Million	NT\$ Million 2023.09.30		2023.06.30			QoQ		2022.09.30		Υ	YoY	
	2023.07		2023.00.30		am	t g%				amt	g%	
Cash & Equivalent	460	38%	516	41%	-56	-119	6	233	20%	227	97%	
Accounts Receivable	241	20%	217	17%	24	11%	>	262	22%	-21	-8%	
Inventory	226	18%	240	19%	-14	-6%	1	353	30%	-127	-36%	
L-T Investments	-	0%	-	0%	0	0%		20	2%	-20	-100%	
Financial assets at fair value through other comprehensive income-non-current	4	0%	5	0%	-1	-10%	6	5	0%	0	-8%	
Total Assets	1,224	100%	1,269	100%	-45	-4%	1	1,177	100%	46	4%	
Fin. Debt	2	0%	4	0%	-2	-44%	6	6	1%	-4	0%	
Accounts Payable	64	5%	76	6%	-12	-16%	6	66	6%	-2	-3%	
Toal Liabilities	211	17%	276	22%	-65	-24%	6	181	15%	30	16%	
Equity	1,012	83%	993	78%	20	2%		996	85%	16	2%	



Consolidated revenue - by product application

REVENUE BY PRODUCT





三. Business Update and Outlook

Admin VP & Spokesman Michael Mai





Optimization of <u>existing</u> <u>customer</u> operations

Close to the needs of customers, and jointly develop future models

Lean manufacturing and R&D technology with synergy

Group manufacturing strengths and established development technology capabilities

Major Pillars

Expanding the <u>market share</u> of medical display

Efforts to develop ODM market for medical display products

Provide total solutions

Solve customers' problems in various situations of medical display use



2024 Outlook

Business Drivers

- The planning schedule for mass production of new models is on schedule.
- Gradual realization of the Group's synergies in accordance with the original planning timetable.

Cautious Measure in the Face of Global Economic Uncertainties



- Economic downturn: The recent war conflict, coupled with the original inflation and interest rate hike, the general economic environment continues to bring challenges to the operation. The medical industry also needs to carefully respond to possible changes in the market and pay attention to the situation of customers delaying orders and shipments.
- Supply and demand situation: We need to pay attention to the changes of customer order schedule, adjust the time point of raw material delivery, to reduce the pressure of inventory accumulation.





四. Q&A



Thank you